

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 August 2003 (07.08.2003)

PCT

(10) International Publication Number
WO 03/063794 A3

- (51) International Patent Classification⁷: **A61K 31/505**, C07D 239/28
- (74) Agents: **PEASE, Ann** et al.; DORSEY & WHITNEY LLP, 4 Embarcadero Center, Suite 3400, San Francisco, CA 94111 (US).
- (21) International Application Number: PCT/US03/03022
- (22) International Filing Date: 31 January 2003 (31.01.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- | | | |
|------------|-------------------------------|----|
| 60/353,333 | 1 February 2002 (01.02.2002) | US |
| 60/353,267 | 1 February 2002 (01.02.2002) | US |
| 60/399,673 | 29 July 2002 (29.07.2002) | US |
| 60/434,277 | 17 December 2002 (17.12.2002) | US |
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/353,333 (CIP)
Filed on 1 February 2002 (01.02.2002)
- (71) Applicant (*for all designated States except US*): **RIGEL PHARMACEUTICALS, INC.** [US/US]; 240 East Grand Avenue, South San Francisco, CA 94080 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **SINGH, Rajinder** [GB/US]; 832 Hillman Avenue, Belmont, CA 94002 (US). **ARGADE, Ankush** [IN/US]; 639-1 Catamaran Street, Foster City, CA 94404 (US). **PAYAN, Donald, G.** [US/US]; 24 Windsor Drive, Hillsborough, CA 94010 (US). **MOLINEAUX, Susan** [US/US]; 23 Tree Top Lane, San Mateo, CA 94402 (US). **HOLLAND, Sacha, J.** [GB/US]; 518 Foerster Street, Apt. B, San Francisco, CA 94127 (US). **CLOUGH, Jeffrey** [US/US]; 3520 Bay Road, Redwood City, CA 94063 (US). **KEIM, Holger** [DE/US]; 25 Buckthorn Way, Menlo Park, CA 94025 (US). **BHAMIDIPATI, Somasekhar** [IN/US]; 888 Foster City Boulevard, #Q2, Foster City, CA 94404 (US). **SYLVAIN, Catherine** [FR/US]; 1425 Bellevue Avenue, #12, Burlingame, CA 94010 (US). **LI, Hui** [CN/US]; 1550 Frontera Way, Apt. 17, Millbrae, CA 94030-2803 (US). **ROSSI, Alexander, B.** [US/US]; 2177 48th Avenue, San Francisco, CA 94116 (US).
- Declaration under Rule 4.17:**
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*
- Published:**
— *with international search report*
- (88) Date of publication of the international search report:
4 December 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES

(57) Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators *via* degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.



WO 03/063794 A3